Date de publication: 27 septembre 2010
Promoteur – Intermédiaire Financier
Pharmathen S.A.
Lieu
Description
The project concerns the promoter’s R&D activities from 2010 to 2013, related to the development of Active Pharmaceutical Ingredients (API) for generic pharmaceuticals, including new manufacturing processes.
Objectifs
The project objectives are to enlarge the company’s generic product offering and develop new drug delivery techniques for originator drugs approaching patent expiry, with the aim of extending protection from generic competition through life-cycle management. Apart from research and development, the project also comprises regulatory approval processes.
Commentaires
Loan foreseen under the Risk Sharing Finance Facility (RSFF).
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 25 million.
Coût total (montant approximatif)
The promoter’s budgeted R&D expenses for the years 2010-2013, i.e. the project costs, are about EUR 55 million.
Aspects environnementaux
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres etc. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.
Passation des marchés
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Statut
Signé - 17/12/2010
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).